XXXX --long-term results following chemotherapy, radiotherapy and combined modality therapy.

@entity1 @entity978 @entity33954 @entity66
215 @entity1 with @entity978 ( @entity978 ) were treated at the Royal Marsden Hospital between 1963 and 1985 (median follow-up 9 years). The actuarial 5- and 10-year survival was 77 and 65%, respectively with 55 and 48% 5 and 10 year disease-free survival. Of 13 variables tested, age was the only independent prognostic indicator for survival on multivariate analysis. @entity1 aged under 40, 40-59 and over 60 years had a 10-year survival of 76, 41 and 8%, respectively (p much less than 0.001). Ninety-one @entity1 were initially treated with combined chemotherapy and radiotherapy (combined modality therapy, @entity33954 ), 73 @entity1 with radiotherapy (RT) and 51 @entity1 with chemotherapy (CT) alone. @entity1 under 40 years treated with @entity33954 achieved the best disease-free survival (10 year disease-free survival: @entity33954 68%; RT 38%; CT 45%). The observed survival advantage for @entity33954 was not statistically significant. In @entity1 aged greater than 40 there was no survival or disease-free survival advantage following @entity33954 . Analysis of recurrence pattern confirmed that @entity33954 improves @entity66 control both at previously involved and uninvolved sites. Recurrences at previously uninvolved sites continued up to 6 years following CT, up to 8 years following @entity33954 and up to 14 years after RT alone. These results indicate that only long-term follow-up gives the true picture of stage III @entity978 .
